Akoya Biosciences, Inc. announced on April 24, 2025, the availability of a new multiplex immunofluorescence (mIF) panel designed to advance antibody-drug conjugate (ADC) development in breast cancer. This new assay will be featured at the American Association for Cancer Research (AACR) 2025 Annual Meeting.
The ADC-focused panel includes key targets such as HER2, TROP2, Ki-67, ER/PR, and a proprietary membrane-localization cocktail, enabling precise patient selection within established breast cancer subtypes. This assay is now available through Akoya’s Advanced Biopharma Services (ABS), which provides comprehensive support from assay customization to reporting.
Additionally, customer-generated real-world data from Akoya’s PhenoCode Discovery IO60 panel, its flagship ultrahigh-plex immuno-oncology solution, will be presented at AACR 2025. This presentation showcases the platform's power in identifying novel biomarkers and predicting patient response, further validating its impact in translational research.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.